Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Eureka Therapeutics
company
About
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series E
- Last Funding Money Raised
- $45M
- Industries
- Biotechnology,Life Science,Medical,Medical Device,Therapeutics
- Founded date
- Jan 1, 2006
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Eureka Therapeutics is a biotechnology company that focuses on immunotherapies for the treatment of cancer. The company's platform is a novel T-cell therapy construct that mimics the natural biology of T-cells to fight cancer. It utilizes a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens.Eureka Therapeutics was founded in 2006 and is headquartered in Emeryville, California.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$45M
Eureka Therapeutics has raised a total of
$45M
in funding over 2 rounds. Their latest funding was raised on
Mar 17, 2020 from a Series E round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 17, 2020 | Series E | $45M | 1 |
Lyell Immunopharma
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Eureka Therapeutics is funded by 1 investors.
Lyell Immunopharma
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Lyell Immunopharma
|
Yes | Series E |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
